Regulatory Approval Overview
On Wednesday, March 11, 2026, the U.S. Food and Drug Administration (FDA) granted approval for Sotyktu (deucravacitinib). The medication is indicated for the treatment of adults suffering from active psoriatic arthritis (PsA). The approval was granted to the pharmaceutical company Bristol Myers Squibb.
Mechanism of Action and Market Innovation
Drug Class: Sotyktu is an oral, selective tyrosine kinase 2 (TYK2) inhibitor.
Clinical Significance: This marks a milestone as the first TYK2 inhibitor to receive FDA approval specifically for the treatment of psoriatic arthritis.
Clinical Trial Foundation: POETYK PsA-1 and PsA-2
The FDA's decision was based on comprehensive data from two pivotal clinical trials:
POETYK PsA-1: Enrolled 670 participants.
POETYK PsA-2: Enrolled 624 participants.
Primary Efficacy: ACR20 Response Rates
The trials measured success primarily through the ACR20 (American College of Rheumatology ≥20 percent improvement). Sotyktu demonstrated statistically significant superiority over the placebo:
PsA-1 Results: 54% of patients on Sotyktu achieved ACR20 vs. 34% on placebo.
PsA-2 Results: 54% of patients on Sotyktu achieved ACR20 vs. 39% on placebo.
Secondary Efficacy: Minimal Disease Activity (MDA)
The secondary endpoint of minimal disease activity response also showed favorable outcomes for the Sotyktu cohorts:
Response Rates: 19% and 26% (Sotyktu) compared to 10% and 15% (Placebo) across the two trials.
Impact on Patient Quality of Life
According to Philip J. Mease, M.D., patients treated with Sotyktu showed marked improvements in the 36-Item Short Form Health Survey Physical Component Summary (SF-36 PCS) score by week 16.
Key Improvement Domains
The treatment positively impacted all four domains of the SF-36 PCS scale:
Physical Functioning
Role-Physical
Bodily Pain
General Health
Safety and Tolerability Profile
The safety data for Sotyktu in the context of psoriatic arthritis was found to be consistent with the profile previously established in patients treated for plaque psoriasis, suggesting a predictable tolerability window for clinicians and patients.
